Myeloablative sibling-matched allogeneic transplantation for adult acute lymphoblastic leukaemia provides the best outcome, but most patients lack a suitable, related histocompatible donor. We reviewed three haematopoietic stem cell donor sources used for alternative donor transplantation pointing out drawbacks of these approaches including inherent selection bias. Matched unrelated donor allografts most often are performed in Philadelphia chromosome-positive disease and in second complete remission (CR2); a nearly 30% event-free survival (EFS) can be anticipated in select patients. Transplants using haploidentical donors are most successful if undertaken in CR1 and CR2 and appear to produce EFS rates of about 25%. Limited umbilical cord blood transplant data suggest efficacy, but marked patient and treatment heterogeneity hamper conclusions. Each of these three strategies has unique potential benefits and disadvantages. The growing use of minimal residual disease detection may identify subgroups of patients unlikely to be cured by chemotherapy alone; these patients are candidates for upfront high-dose chemoradiotherapy and cellular immunotherapy. These three approaches are plagued by treatment-related mortality and relapse rates as high as 40%, but advances in technology and supportive care may make each stem cell source more feasible and efficacious.
Introduction
Treatment results for adult acute lymphoblastic leukaemia (ALL) are disappointing and the rate of progress is slow. Conventional chemotherapy, an arduous, toxic and drawnout therapy is at best successful in providing long-term benefit for only one-third of patients and currently there is no proven role of autografting in patients in first complete remission (CR1), although the results of a multi-national, multicentre randomized trial comparing autograft with chemotherapy will be known soon. 1 Adults in this review refer to patients 20 years and above.
Allogeneic haematopoietic stem cell transplantation (HSCT) with matched sibling donors is currently used for high-risk adult ALL patients in CR1 and for relapsed disease patients who achieve a second complete remission (CR2). Two French studies, using 'biological assignment' demonstrated efficacy of sibling allografting in CR1 when compared to 'best alternative therapy'. Attal et al. 2 in 1995 compared post-remission therapies in 572 patients using allograft in those with a sibling-matched donor, whereas the others were randomized to chemotherapy or autograft. Five-year survival in the allogeneic transplant cohort was superior to the other groups (46 vs 31%, P ¼ 0.04). Recently, the 10-year follow-up results confirmed the marked superiority of allogeneic transplant to chemotherapy (44 vs 11%, P ¼ 0.009). The GOELAMS group reported via an intent-to-treat analysis in adult ALL patients oage 50 years with at least one high-risk feature; at 6 years, an allograft was superior compared to an autograft 3 (75 vs 40%, P ¼ 0.027). Most patients do not have a suitable histocompatible sibling donor for an allograft and the use of alternative donors usually has been reserved for CR2. When undertaken in relapse after autotransplant or conventional chemotherapy treatment, the results of salvage alternative donor transplantation are poor. 4 Unrelated donor (UD) HSCT, however, is regarded as standard therapy in adults with Philadelphia chromosome-or BCR-ABL fusion gene reverse transcription-PCR-positive ALL. For the remaining patients, the challenge is to improve upon alternative donor transplantation so that the patient outcome data approach those obtained using sibling allogeneic transplantation for adult ALL; at this juncture, some published studies 5, 6 currently do not show wide differences. Few large-scale data are available, however, that describe longterm outcome for such patients. This review will address the timing and choice of using three disparate alternative donor allografts, for example, UD, haploidentical donor and umbilical cord blood (UCB) grafts in the outcome of full-intensity (myeloablative) transplant regimens. The optimal myeloablative conditioning regimen remains to be identified, although a recent comparison in the sibling allograft setting may shed light on the issue. 7 Factors influencing the outcome of ALL and rationale for allogeneic HSCT For subsets of adult ALL patients, allogeneic HSCT probably is considered standard therapy. Patients in CR2 or subsequent remissions have no more than a 5% chance of prolonged survival with further chemotherapy and only a 10-15% chance using high-dose chemoradiotherapy and autologous HSCT. 4 Similarly, patients with Philadelphia chromosome (or BCR-ABL)-positive ALL have a o5% chance of attaining 5-year survival with chemotherapy. In spite of the introduction of imatinib and the ability of this agent to induce molecular remissions, autotransplantation has not yet been shown to have curative potential.
Other CR1 patient subsets may have such a poor outcome with chemotherapy that the intervention of alternative donor HSCT and its inherent risks of high treatment-related mortality (TRM) may be justified. These factors include patients with a presenting white blood cell (WBC) count exceeding 30 Â 10 9 /l for B-cell disease and 100 Â 10 9 /l for T-cell disease, near haploid ALL and slow tempo to attain CR1 (44 weeks). Patients with t(4;11) and complex cytogenetics also have an extremely poor outcome with chemotherapy. 8 Prognostic factors, although better understood in patients with childhood ALL, have been re-examined in adults in the recently published Medical Research Council (MRC)/Eastern Cooperative Oncology Group (ECOG) study. 1 
Basic principles
Grafts obtained from donors matched molecularly at human leucocyte antigen (HLA)-A, -B, -C and DR with the recipient result in a superior outcome. 9 Mismatching at the DQ locus is of less significance in most studies, and large male donors who are cytomegalovirus (CMV) serocompatible are preferred. Mismatching at a single DP locus, although not an option for many transplant candidates, reduces the relapse rate in patients with acute myelogenous leukaemia (AML). 10 Peripheral blood stem cell (PBSC) grafts have not been shown to be superior to marrow in the full-intensity UD bone marrow transplant setting, 11 but may be preferable when the recipient weighs 20% more than the recipient.
Hierarchy of alternative donors
Few large-scale studies compare these forms of alternative donor transplantation and the choice of stem cell source will also be influenced by clinical urgency and the time taken to procure haematopoietic stem cells. Single centre results must be analysed carefully when deciding what plan to recommend in the individual patient. If a matched sibling donor is not available, some data 12 indicate that a single antigen mismatched family donor allograft may result in the same outcome as using a matched UD, but this review will not consider this category of donor further. If there is no molecularly matched UD, then a single allele mismatched UD, an UCB donor or a haploidentical stem cell donor are also possibilities.
Specific indications for UD HSCT in adult ALL
ALL in second complete remission The most common indication for UD-HSCT in adult ALL patients is for those in CR2. In those subjects lacking a sibling donor, the other options are use of a purged or unpurged autologous PBSC transplant. Autotransplants are associated with a high chance of relapse but a low TRM. The results of purged autografts (with antibodies or cyclophosphamide derivatives) are disappointing as major series report only 10-15% disease-free survival (DFS). 13, 14 In a combined study of two large centres, there was a trend for UD-HSCT to be superior to autologous HSCT in the under age 18 years group, whereas similar results were noted for the two therapeutic modalities in the older patients. 15 Weisdorf et al., 16 on behalf of the International Bone Marrow Transplant Research (IBMTR), performed a retrospective comparison of these two modalities. Threeyear survivals in the UD-HSCT and autograft groups were 40 and 32%, respectively (P ¼ NS), but the UD-HSCT cohort had more patients with high-risk features such as unfavourable karyotypes and high WBC counts at diagnosis. This report is limited by inherent selection bias, its retrospective nature and a high TRM (more than 40% in the UD-HSCT cohort). The benefit of low leukaemic relapse in the UD-HSCT cohort is not advantageous, until the high TRM is reduced.
The duration of CR2 in adults is brief and patients must proceed rapidly to transplantation. There are no large published adult reports, but some important facts can be gleaned from the paediatric data. 17 In a large series of Tdepleted UD-HSCT for ALL (including 88 in CR2), relapse was seen in up to 40%, the majority occurring in the first year after transplant; approximately 40% attained relatively long-term survival. Disease recurrence after transplantation appears to be a big problem in those who relapse while receiving conventional therapy and who have a high level of minimal residual disease (marrow involvement) immediately before transplantation. 18 The probability of relapse may be decreased by using T-replete transplants at the expense of more acute and chronic graft-versus-host disease (GVHD) and a higher TRM. 19 On the other hand, relapse after allograft remains problematic as the chance of response to donor lymphocyte infusion (DLI) is very low (at 18 and 5% in the two largest published series 20, 21 ) and usually is not durable. The possibility of using pre-emptive DLI in those subjects at high risk of relapse has been investigated in children and it may be possible to apply these techniques to adults. 22 The Bristol unit has performed UD-HSCT on 16 patients median (range) age 23 years in CR2 and eight survive. All patients received T-cell-depleted grafts predominantly using Campath-1M or -1H. Actuarial DFS is 46716% (7s.e.) at 18 months with a median follow-up of 19 months (DI Marks, unpublished data). Two of these 16 patients have relapsed, both at less than 4 months after UD-HSCT.
To summarize, UD-HSCT has a greater antileukaemic effect than an autotransplant and may be the treatment of choice for patients in CR2 at high risk of relapse such as those with an unfavourable karyotype or marked leucocytosis at diagnosis, or a CR1 of short duration. Outcomes are better when the patient is young and the donor is well matched with the recipient.
Philadelphia-positive ALL Philadelphia chromosome-positive ALL remains the clearest indication for UD-HSCT in CR1. Chemotherapy alone achieves remission in over three-quarters of patients, but remissions are brief. 23 Although there are encouraging reports of cures in children with very intensive chemotherapy, particularly in those who present with a WBC counts o25 Â 10 9 /l, 24 this observation has not been reproduced in adult patients. Autologous HSCT is another potential option for patients with Philadelphia chromosome-positive ALL and it may be possible to collect a BCR-ABL-negative graft, 25 but there are no long-term data to support the use of autotransplantation for this disease. This therapeutic option will need to be re-visited with the advent and implementation of imatinib.
Sierra et al. 26 in Seattle reported 18 patients (median age 25 years) who had T-replete UD-HSCT for Philadelphia chromosome-positive ALL. Forty-nine per cent survived leukaemia-free at 2 years. The incidence of grade II-IV acute GVHD and extensive chronic GVHD were 78 and 50%, respectively, and the incidence of relapse was 28%. Marks et al. 27 in Bristol reported 15 children and young adults treated with T-depleted UD-HSCT (nine in CR1 and six with more advanced disease, median age 5 years) who had 2-year DFS and overall survivals of 37 and 44%, respectively. Five of nine subjects transplanted in CR1 survived, although one survivor developed a second tumour. The incidence of acute and chronic GVHD was much lower than observed in the Seattle series 25 but that result, in part, is explained by the younger age of the patients. Six of 15 patients relapsed (40%), not significantly more than would have been expected if the grafts were T-replete.
Available data suggest that patients who are referred for transplantation in CR2 still can be cured, 26, 27 and there is clinical urgency to perform a transplant as CR2 in this disease are brief. Barrett et al. 28 from the IBMTR found that sibling allografts cured a proportion of patients not in remission; there are no data in the UD setting that can help us decide whether it is reasonable to offer UD-HSCT to these patients.
UD HSCT for Philadelphia chromosome-negative ALL in CR1
UD-HSCT is increasingly used for adults with ALL in CR1 who present with high WBC counts or other poor prognostic features identified by Hoelzer et al., 29 but there are no randomized studies or large series reporting outcome. The use of alternative donor transplant may extend beyond this high-risk group. The chance of cure of adult ALL using modern chemotherapy protocols is only about 30%. Outcome using myeloablative sibling-matched donor allografts in CR1 ALL is excellent; if the TRM of UD-HSCT can be lowered to approach that of sibling donor HSCT, then this approach will become a reasonable therapeutic option.
Worldwide results of this intervention are not known and the Center for International Bone Marrow Transplant Research (CIBMTR) is studying the subject. The MRC and ECOG (UKALL XII/ECOG 2993) have collected data on 33 high-risk adult ALL Philadelphia chromosome-negative patients in whom both investigators and patients chose to proceed with an UD-HSCT in CR1. 30 Median patient age was 27 years; 40% of evaluable patients had highrisk cytogenetics, one-third had an initial WBC count 4100 Â 10 9 /l and one-third had not achieved CR by day 56 of induction therapy. Albeit in a small group, the results are encouraging: TRM was 30% and DFS was 56% with no fatal events occurring after 15 months. Further, there appears to be a survival plateau as 14 patients are alive more than 3 years after UD-HSCT. The median time from diagnosis to transplant was 7 months providing hope that earlier transplant may be associated with a lower TRM.
Such data can be used to support the design of clinical trials to test this hypothesis. If we make the assumption that high-risk patients with well-matched UD grafts will attain an approximately 50% DFS, it seems reasonable to target patients who have a predicted, non-transplant therapy survival of less than 25%. A doubling of survival may justify the high TRM of 25-30%. Hypodiploidy and a WBC count at diagnosis 4100 Â 10 9 /l appear to meet these criteria.
ALL not in remission
Less than 10% of adult ALL patients fail to attain CR; their outcome is dismal, despite allografting using any donor owing to high TRM and high probability of early relapse. Further, at least one-third of patients with relapsed ALL do not respond to salvage chemotherapy and transplantation in the setting of overt disease is futile. These patients are candidates for novel therapies such as clofarabine and monoclonal antibodies such as alemtuzamab or rituximab; if these therapies are successful, there may be a small chance of cure using an allograft.
It should be pointed out that the definition of remission is changing and investigators using various methods can detect small amounts of residual disease; some patients in morphologic but not molecular remission may be curable and the CIBMTR currently is studying this issue. Patients truly refractory to modern chemotherapy may not be curable.
Minimal residual disease: issues and challenges
Multiple studies conducted in children and adult ALL patients indicate that inadequate eradication of disease at various time points after chemotherapy is associated with a low probability of prolonged DFS. 31, 32 Minimal residual disease can be assessed by molecular detection of immunoglobulin heavy-chain gene rearrangements or T-cell receptor gene rearrangements or by flow cytometric detection of cells bearing the diagnostic immunophenotypic clone. Such techniques have a sensitivity sufficient to detect one malignant cell in 10 4 normal cells. There is no proof that allogeneic transplant can eradicate leukaemic cells resistant to standard dose chemotherapy. Given the fact that such patients have an extremely poor outcome, it seems reasonable to explore allografting, including the use of UD in this group. Transplant offers both high-dose chemoradiotherapy and the application of a potential graft-versus-leukaemia effect. Regular monitoring of chimerism and the consideration of adjustment of mixed chimerism using withdrawal of immunosuppression or administration of DLI may improve outcome. 22 The optimum timing of transplant in patients with minimal residual disease is uncertain. Theoretically, it might be desirable to provide therapy that renders the patient minimal residual disease negative before proceeding to transplant, but overt relapse can occur in a very short time and future trials likely will recommend performing an allograft as soon as practicable.
Haploidentical HSCT
Evolution in protocols Trials using full haplotype mismatched transplants have been proceeding for over 20 years. Initial outcomes in leukaemia patients were disappointing because of the high incidence of severe GVHD in T-replete transplants and high rejection rates in T-cell-depleted transplants. 33, 34 Over the past decade, the Perugia group has shown that full haplotype mismatched transplants can be successful in CR1 and CR2 ALL adult patients when a megadose of extensively T-cell-depleted stem cells is infused after an immunomyeloablative conditioning regimen. [35] [36] [37] [38] [39] Since the first report in 1994, 35 the approach has been modified extensively. In 1995, fludarabine replaced cyclophosphamide in the TBI-based conditioning regimen in an attempt to reduce conditioning regimen toxicity without jeopardizing immunosuppressive effect. 40 Other advances include an implementation of an automated CD34 cell-positive selection apparatus that provided an efficient 4.5 log T-cell depletion. Further, these investigators recognized the need to avoid granulocyte colony-stimulating factor (G-CSF) after transplant, as use of this agent impairs dendritic cell ability to produce IL-12 causing abnormalities in antigenpresenting cell functions and T-cell reactivity. Elimination of G-CSF prevents this immune dysregulation and accelerates functional immune recovery. 41 Clinical experience Since 1993, 65 adult patients with high-risk ALL have undergone transplantation using haematopoietic cells obtained from haploidentical donors (Table 1) . Patients ranged in age from 18 to 51 (median 26) years and all were at high risk for leukaemia relapse because of advanced disease status at the time of transplant (23 in relapse, 23 in second or later CR). The 19 patients in CR1 also had unfavourable prognostic features (poor-risk cytogenetics in 15 patients, slow tempo to CR in two patients and high WBC cell count at presentation in two patients). All patients received single-fraction 8 Gy TBI at dose rate of 16 cGy/min with lung shielding after 4 Gy. Radiation was followed by thiotepa (5 mg/kg for 2 consecutive days) and either cyclophosphamide (40 mg/kg for two consecutive days) in the first 11 patients or fludarabine (40 mg/m 2 for 5 days) in the others. Rabbit antithymocyte globulin (ATG) was given at either 25 mg/kg (Fresenius, Bad Homburg, Germany) or 6 mg/kg (Genzyme, Cambridge, MA, USA), administered over 5 days. Other modifications of the haploidentical transplantation procedure are shown in Table 2 . No immune suppression for GVHD prophylaxis was given after transplantation. Recipients of CD34 positively selected grafts received a median (range) of 13.6 
Clinical outcomes
Engraftment and GVHD. The grafts contained a similar number of T-lymphocytes as the threshold dose established to prevent GVHD in severe combined immunodeficient patients who received mismatched transplants without post-transplant immunosuppressive therapy. 42 Primary engraftment was achieved in 59 (91%) patients. The six patients who rejected the first graft engrafted after second transplants. Rejection was reversed by transplanting immunoselected CD34 þ cells from the same donor in two patients and infusion of haematopoietic stem cells from four different donors. In these second transplants, patient received additional conditioning that consisted of cyclophosphamide 80 mg/kg and 5 days each of ATG 1.2 mg/kg/ days and fludarabine 40 mg/m 2 /days. Severe (grade III-IV) acute GVHD occurred in only four patients (three after second transplantation); three evolved to chronic GVHD. Another six patients developed acute GVHD after DLI that were given to 21 recipients with the aim of accelerating immunological recovery and preventing leukaemia relapse. The DLI doses were 1 Â 10 4 CD3 cells/kg infused 40 days after transplant; if no GVHD was observed, additional cells (3 Â 10 4 CD3 cells/kg) were given on days 100 and 180. Non-leukaemic mortality. Seventeen of the 29 non-leukaemic deaths were caused by infections (aspergillus ¼ 6, CMV ¼ 6, adenovirus ¼ 1, Epstein-Barr virus ¼ 1 and pseudomonas ¼ 3). The cumulative incidence of nonleukaemic mortality was 45%. No fatalities, however, occurred after the first year in the absence of chronic GVHD and immunosuppressive therapy. This high transplant-related mortality is mainly due to slow immunological recovery. In haploidentical transplants, extensive T-cell depletion is required to prevent GVHD, so that the T-cell repertoire is limited and the ATG in the conditioning likely delays T-cell homeostatic expansion. Several strategies are under investigation to accelerate post-transplant immune recovery. The Perugia group has recently developed a means for transferring donor pathogen-specific immune responses safely across the HLA barrier. 43 Large numbers of donor T-cell clones raised against Aspergillus fumigatus and CMV antigens were screened for crossreactivity to host alloantigens using mixed lymphocyte reaction. Non-host-reactive clones, presumably devoid of GVHD potential, were pooled and infused into recipients soon after transplant. Untreated patients developed Aspergillus-and CMV-specific T-cell responses in vitro more than 9 months after transplant. All patients who had received the infusions exhibited Aspergillus-and CMV-specific responses within 3 weeks, for example, 5 weeks after transplant and no patient developed GVHD.
Leukaemia relapse. In 65 high-risk adult ALL patients, disease status at transplantation was the major risk factor for relapse. The cumulative 2-year incidence of relapse for the 42 patients transplanted in remission was 24%, but was 50% for the 23 patients transplanted in relapse (Po0.001). Leukaemic relapse risk may be higher in T-cell-depleted transplants because of the lack of GVHD-related graftversus-leukaemia effect. 44 In this setting, a 20% relapse rate is expected. The intense myeloablative TBI-based conditioning regimen probably compensated for the lack of Tcell-mediated graft-versus-leukaemia effect.
Event-free survival. Overall, 14 (21.5%) patients survive at a median (range) follow-up of 42 (range 2-123) months. Event-free survival (EFS) correlates with disease status at transplant. For patients in either CR1 (high-risk) or second or subsequent CR at transplant, EFS are 2870.11 and 2370.09%, respectively. For the 23 patients transplanted in relapse, survival is poor (Figure 1 ) and similar to other adult high-risk ALL patients who received transplants from any alternative donors. In the absence of immunosuppressive therapy and the low incidence of chronic GVHD, quality of life is excellent in survivors (100% Karnofsky score 8-12 months post-transplant).
USA data
Henslee-Downey and co-workers 45 reported in 2004 an update of their pioneering experience using partially mismatched family donors for 201 patients with acute leukaemia. There were equal numbers of ALL and AML patients and it is not possible to separate the two diseases in the report. Only 28% of these patients were in CR1 or CR2 at the time of transplant. All patients received TBI-based regimens and were given cyclosporine, corticosteroids and ATG to prevent GVHD. The monoclonal antibodies T10B9 or OKT3 were used in vitro for T-cell depletion of the graft. TRM was 51% at 5 years in the whole group, with infection being a prominent cause of death. The incidence of acute and chronic GVHD was 13 and 15%, respectively, and 31% relapsed. Overall survival at 5 years was 29 and 34% for CR1 or CR2 patients, respectively.
Conclusions
Haploidentical transplant results have been improved; the high rejection rate and incidence of severe GVHD are reduced by combining high-intensity conditioning and an infusion of a large dose of purified stem cells in adult ALL patients transplanted in CR1 or CR2. These data, however, 
UCB transplantation
The data for use of UCB transplants in adult ALL are difficult to interpret. Laughlin et al. 46 reported the use of myeloablative UCB transplants in 68 adults, 15 of whom had ALL (N ¼ 8 CR1/CR2; N ¼ 7 advanced disease). Nineteen patients are alive and 18 disease-free at a median (range) follow-up of 22 (range 11-51) months. There were no statistically significant differences in EFS according to the type of malignant disorder (P ¼ 0.61). A subsequent publication 47 for the period 1996-2001 included 45 adult ALL patients given UCB grafts that were compared to 82 subjects receiving matched-unrelated or 17 one-antigenmismatched UD grafts. EFS did not differ among the disease entity subtypes, for example, AML, ALL, chronic myelogenous leukaemia or myelodysplastic syndrome. Overall EFS, however, was best in patients receiving matched-UD allografts but equivalent survival when comparing one-antigen mismatched UD graft and twoantigen mismatched UCB grafts.
Rocha et al. 48 retrospectively analysed 73 adult ALL patients (more than half with advanced disease) receiving UCB transplants in European transplant centres during the period 1998-2002. The 2-year leukaemia-free survival was 36% and 2-year cumulative incidence of TRM and relapse were 41 and 23%, respectively.
The University of Minnesota presented a preliminary communication in which they addressed the impact of donor stem cell source on outcome in 126 adult ALL patients median (range) age 31 years receiving a cyclophosphamide 120 mg/kg and fractionated TBI 1320-1375 cGy regimen. 49 Twelve patients received UCB grafts and when compared to matched-related, matched-UD and mismatched donor grafts had a superior 1-year overall (75%) and leukaemia-free (67%) survival. Relapse rates and TRMs were also improved at 8 and 25%, respectively. Their data demonstrated that GVHD was associated with an improved leukaemia-free survival, suggesting a significant graft-versus-leukaemia effect with all allogeneic donor sources.
The MD Anderson Cancer Center has reported the results of ongoing UCB transplant trials for adult ALL patients median (range) age 37 years in which they employ either a fludarabine/TBI/ATG or fludarabine/ melphalan/thiotepa/ATG regimen. 50 Fifteen adult ALL patients (N ¼ 3 CR1; N ¼ 8 CR2; N ¼ 4 relapse) were given four of six HLA-matched UCB grafts. Four subjects are alive disease-free at a median (range) of 11.5 (3-31) months after transplant. Eleven patients died at a median (range) of 6 (1-22) months owing to GVHD (N ¼ 4), relapsed disease (N ¼ 6) or engraftment failure (N ¼ 1) .
The group at Roswell Park Memorial Institute performed six UCB transplants in adult ALL patients median (range) age 23 (13-41) years using cyclophosphamide/TBI/ ATG (N ¼ 4) and one each busulphan/cyclophosphamide/ ATG or melphalan/TBI/ATG over the period 1997-2001. 51 None of the patients developed acute GVHD. One patient died early at 19 days and one died at 77 days owing to engraftment failure. Three patients have relapsed but three are alive at 2 years.
Chao and co-workers 52 have performed a total of 18 (17 myeloablative and one reduced-intensity conditioning) UCB transplants for ALL during the period 1996 through 2004. Median (range) patient age was 34 years; most subjects received UCB grafts matched at 4/6 HLA loci, but in two instances the graft was a 3/6 match, whereas in three cases a 5/6 HLA match was located and infused. Two patients failed to engraft, 11 died from treatmentrelated causes, whereas two succumbed to tumour progression. Three patients remain alive at 1 year, and 9 and 10 years after allograft.
Summary of UCB transplantation experience
It is not easy to use these data to advise investigators how to approach potential patients. Small patient numbers, heterogeneity of remission status, variability of matching and incomplete information about UCB cell dose make data summary difficult. These results may not differ from UD grafts and relapse remains a significant issue as does engraftment failure. Somewhere between 20 and 50% of patients in CR1 and an occasional CR2 patient can become long-term survivors. Double UCB transplants are not represented in these data and may represent an advance, particularly addressing the issue of engraftment.
Future considerations
It is highly unlikely that randomized head-to-head comparisons of the three stem cell sources will be performed and investigators may base choice of approach upon observational or registry retrospective comparison data for decision making.
Clearly, these strategies require refinement for improving patient outcome.
A comparison of the advantages and disadvantages of each of these three modalities is illustrated in Tables 3 and 4. UD allografts are plagued by high TRM and it remains to be proven that use of reduced-intensity conditioning will overcome this drawback. 53 Further, GVHD continues to account for a sizeable morbidity and mortality; new and novel interventions such as the use of potentially more effective anti-GVHD therapies including sirolimus and mesenchymal stem cells await confirmation as adding efficacy. 54, 55 Haploidentical HSCT is ineffective when performed in the setting or far-advanced or active disease and its efficacy are marred by a myriad of opportunistic infections. Although cellular-based therapies could reduce the latter, such a technique appears very cumbersome and expensive as it is performed generally on a case-bycase basis. 56, 57 Implementation of new supportive care strategies, especially earlier use such as better anti-microbial agents, that is, maribavir for CMV infection, may be of considerable benefit. Combination anti-fungal therapy or new anti-fungals such as posaconazole also may improve patient outcome. [58] [59] [60] UCB transplants still are in an early stage of development. This graft source has the potential advantage of the most readily available source, but contain small cell numbers in a graft which, in general, is less histocompatible than UD grafts, yet relapse rates remain high. Investigations underway to advance this field include ex vivo UCB unit expansion and use of double UCB grafts in the setting of reduced-intensity conditioning; the latter appears to provide greater anti-leukaemic benefit. 61 Further, some groups are exploiting the potential for improving the relapse rates via use of KIR-mismatching cells in which 'third party' (other donor) cells will be infused along with the UCB graft to improve graft-versus-tumour effect. Large-scale data still are awaited. 
